<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333745</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300004693</org_study_id>
    <nct_id>NCT04333745</nct_id>
  </id_info>
  <brief_title>Body Mass Index (BMI) and Calcium Oxalate Stone Disease</brief_title>
  <official_title>Body Mass Index (BMI) and Calcium Oxalate Stone Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether there are differences in endogenous oxalate synthesis
      between stone formers and non-stone formers and whether obesity impacts levels of oxalate in
      blood and urine. Participants will consume a controlled low-oxalate diet and provide blood
      and urine samples to measure the amount of oxalate in their bodies. They will then ingest an
      oral load of oxalate and provide additional blood and urine samples to measure any increase
      in oxalate levels.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Oxalate Excretion</measure>
    <time_frame>Baseline through Day 6</time_frame>
    <description>Urinary oxalate excretion from urine samples will be measured as mg/day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume the controlled diet for five days and ingest an oral load of oxalate. Participants will provide urine and blood samples both before the oxalate load to establish baseline levels and after the oxalate load to measure oxalate levels afterwards</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Controlled Diet</intervention_name>
    <description>Participant will consume a controlled low oxalate diet for five days</description>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral Oxalate Load</intervention_name>
    <description>Participant will come to the Clinical Research Unit (CRU) at UAB and consume 4 mmoles of sodium oxalate containing 50 mg carbon-13 oxalate, prepared in 100 mls bottled water.</description>
    <arm_group_label>Controlled Dietary Study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) less than 25 or greater than 30

          -  Willingness to consume controlled diet

          -  Willingness to stop supplements/aids for 10 days before start and during study
             (including probiotics, vitamins, calcium and other minerals, herbal supplements, and
             nutritional supplements).

          -  For stone forming group, willingness to stop stone prevention medication (thiazide,
             allopurinol, alkali) for 10 days before start of study and during study.

          -  For stone forming group, a screening urinary oxalate result &gt;30mg/24hr.

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Primary and/or enteric hyperoxaluria

          -  Distal renal tubular acidosis

          -  Primary hyperparathyroidism

          -  Estimated Glomerular Filtration Rate (eGFR) &lt;60 ml/min/1.73m^2

          -  Abnormal fasting comprehensive metabolic panel (CMP)

          -  Hemoglobin A1c (HbA1c) result&gt;60

          -  Pregnancy

          -  2 x 24hr urine creatinine results greater than 20% of normal range (17-28 mg/kg)

          -  24hr urinary calcium &gt;300mg/24hr
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle D Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Demond Wiley</last_name>
    <phone>205-934-3671</phone>
    <email>kidneystone@uabmc.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Kyle D. Wood</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>oxalate</keyword>
  <keyword>kidney stone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Calculi</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

